Endocrine Abstracts

Introduction: The best timing for PRRT (peptide receptor radionuclide therapy) in the case of pancreatic neuroendocrine tumors (panNETs) is still to define, as randomized prospective trials are lacking. Recent studies suggest that some systemic therapies can affect response to PRRT, favoring an earlier use of the latter.Objective: To determine the efficacy and toxicity of PRRT, comparing its results when used as a second line systemic therapy (a...